Revvity Scopolamine Methyl Chloride, -, 25

Revvity 250µCi quantities of Scopolamine Methyl Chloride, [N-methyl-³H]-, are available for your research. Scopolamine is a natural product antagonist of muscarinic acetylcholine receptors, and is used to treat motion sickness and nausea. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (B_max), dissociation constants (K_d), association and dissociation rates (k_on and k_off), and inhibitor constants (K_i) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, Revvity has been a leading supplier of New England Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity References for NET636: - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Michael Salmon, Mark A. Luttmann, James J. Foley, Peter T. Buckley, Dulcie B. Schmidt, Miriam Burman, Edward F. Webb, Christopher J. DeHaas, Charles J. Kotzer, Victoria J. Barrett, Robert J. Slack, Henry M. Sarau, Michael R. Palovich, Dramane I. Lainé, Douglas W. P. Hay and William L. Rumsey, Pharmacological Characterization of GSK573719 (Umeclidinium): A Novel, Long-Acting, Inhaled Antagonist of the Muscarinic Cholinergic Receptors for Treatment of Pulmonary Diseases, Journal of Pharmacology and Experimental Therapeutics May 2013, 345 (2): 260-270.Weng-Keong Loke, Meng-Kwoon Sim, Mei-Lin Go, O-Substituted derivatives of pralidoxime: muscarinic properties and protection against soman effects in rats, European Journal of Pharmacology, 2002, 442 (3): 279-287.